A Rare Case of Metastatic Heterogeneous Poorly Differentiated Neuroendocrine Carcinoma of Ileum: A Case Report and Literature Review

Andrei Nikiforchin, MD 1, Ruth Y. Peng, MD 2, Michelle Sittig, RN 3 and Sandy Kotiah, MD 4

1Department of Surgical Oncology, Mercy Medical Center, Maryland, USA  
2Department of Pathology, Mercy Medical Center, Maryland, USA  
3Department of Surgical Oncology, Mercy Medical Center, Maryland, USA  
4Department of Medical Oncology and Hematology, Mercy Medical Center, Maryland, USA

*Corresponding author: Sandy Kotiah, MD, Department of Medical Oncology and Hematology, Mercy Medical Center, 227 Saint Paul Place, Baltimore, Maryland, 21202, USA, Tel: 410-783-5858

Abstract
Neuroendocrine neoplasms (NENs) represent a diverse group of tumors arising from neuroendocrine cells. Current World Health Organization (WHO) classification is based on tumor differentiation and grade defined by mitotic rate and/or ki-67 index to determine prognosis and treatment options. However, some NENs do not meet WHO pathology criteria due to morphologic heterogeneity and this leads to management challenges. WHO defines poorly differentiated NENs of the GI tract as having morphologically large or small cell features with marked elevation of ki-67. We present a unique clinical case that does not fit either growth pattern and also has heterogeneity with a well-differentiated component. This case report and literature review highlights the current limitations of the WHO classification of small bowel NENs and the subsequent challenges in management decisions for the patients.

Keywords  
Neuroendocrine neoplasm, Neuroendocrine carcinoma, Tumor grade, Morphologic heterogeneity, WHO classification

Introduction
The small bowel is the most common location of neuroendocrine neoplasms (NENs) [1,2]. The majority of small bowel NENs are found in the ileum and typically represent well-differentiated low-grade (G1) histopathologic type whereas, poorly differentiated high-grade (G3) type is a quite rare finding [1,3-7]. Despite the favorable prognosis in G1 histology, approximately 48% of patients with ileum NENs present with distant disease at diagnosis and 14-17% have peritoneal carcinomatosis (PC) [1,2,8-10].

Currently, the treatment of advanced ileum NENs varies from surgical options, liver directed therapy, everolimus and somatostatin analogues for G1-G2 well-differentiated neuroendocrine tumors (NETs), to systemic chemotherapy for G3 poorly differentiated neuroendocrine carcinomas (NECs) [11,12]. Therefore the grade and differentiation of a tumor in accordance with the current World Health Organization (WHO) classification is an important step for clinical decision making in these patients [5,7]. However, several studies have shown that gastroenteropancreatic (GEP) NENs can demonstrate heterogeneity in their proliferative rate/grade between the primary site and metastases [13,14]. This heterogeneity leads to challenges in diagnosis and appropriate treatment options.

In this report, we present a rare case of metastatic...
unremarkable medical, social, and family history, underwent an incisional hernia repair. During surgery, peritoneal carcinomatosis was incidentally found with final biopsy histopathology revealing a well-differentiated G1 NET with ki-67 < 3% and mitotic rate of < 1 per 10 high-power fields (HPF). Preoperative computed tomography revealed a mesenteric mass measuring 2.1 × 1.8 × 3.1 cm (Figure 1) and a single right hepatic lobe lesion measuring 1.1 × 1.0 cm. Ga-68 DOTATATE PET-MRI described a 1.9 × 2.8 cm lesion in the small bowel, a 2.2 × 2.1 cm mesenteric nodule, one small liver lesion and several peritoneal lesions with active tracer uptake (Figure 2a, Figure 2b, Figure 2c and Figure 2d). The patient complained of frequent bowel movements daily during previous 6 months. A 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) level was elevated to 10.6 mg. Other laboratory results were within normal limits.

Somatostatin analog therapy was initiated due to diarrhea and elevated 5-HIAA. The case was discussed in multidisciplinary tumor board and the patient underwent cytoreductive surgery (CRS). The primary tumor site was the terminal ileum with 5 small liver metastases as well as extensive peritoneal involvement. The peritoneal cancer index was 26 and a complete heterogeneous ileum NEC, accompanied by a literature review.

**Case Report**

A 67-year-old African American female with an

---

**Figure 1:** Abdominal CT scan of mass (arrow) involving mesentery compatible with a neuroendocrine tumor measuring approximately 2.1 × 1.8 cm in orthogonal axial dimensions and up to 3.1 cm in craniocaudal extent. CT: computed tomography.

**Figure 2a:** Ga-68 DOTATATE PET-MRI shows a prominent somatostatin avid lesion (arrow) measuring 1.9 × 2.8 cm with SUV 28 within a loop of distal small bowel. Ga-68 DOTATATE PET-MRI - positron emission tomography-magnetic resonance imaging with Gallium-68; SUV: standardized uptake values.

**Figure 2b:** Well-defined 2.2 × 2.1 cm lesion (arrow) with prominent tracer uptake (SUV 22.3) adjacent to the small bowel mesentery.

**Figure 2c:** Ga-68 PET-MRI displays a tiny focus (arrow) measuring 1.9 × 2.8 cm with SUV 28 within a loop of distal small bowel.

**Figure 2d:** Small peritoneal lesion (arrow) with high tracer uptake consistent with peritoneal carcinomatosis.
cytoreduction was achieved (CC-0).

Postoperative pathology reported a heterogeneous poorly differentiated G3 NEC (Figure 3a and Figure 3b) with perineural invasion (Figure 4), regional lymph node metastases, liver, and peritoneal involvement. The ki-67 index varied within the tumor, ranging from 3% to 25% (Figure 5a and Figure 5b) and up to 19 mitotic figures per 10 HPF (Figure 6). Features were not consistent with either small or large cell type histology. Molecular testing did not yield any targeted mutations or immunotherapy markers. The patient is currently undergoing treatment with somatostatin analog for her functional tumor and is asymptomatic without any signs of recurrence at 6-months follow-up.

Discussion

This patient was initially diagnosed after peritoneal
biopsy with a resectable metastatic G1 INET. One of the current standards of care for metastatic well-differentiated G1-G2 NETs is surgical resection when feasible to achieve remission [11,12,15]. Surgical approach is offered to patients with liver metastases when debulking of ≥ 70% of the liver metastases is possible [16-18]. Retrospective data also states that CRS provides a survival benefit in selected patients with PC of well-differentiated NETs origin, while the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) does not improve outcomes [10,19]. The patient underwent extensive CRS without HIPEC and the final surgical histopathology revealed a poorly differentiated G3 NEC with several non-typical features.

There have been many attempts to establish a classification of NENs covering all tumor subtypes in an effort to clarify treatment options and prognosis. However, the creation and clinical application of NENs classification remains challenging due to significant heterogeneity of these tumors [14,20]. The most recent updated version of WHO classification is based on cell differentiation, mitotic rate, and ki-67 index [7,21]. It divides all GEP NENs into four groups: G1 NET, G2 NET, small cell G3 NEC, and large cell G3 NEC [5,7]. The subdivision of small and large cell G3 NECs arose from lung NECs due to similar morphology, tumor behavior, and treatment response [22-24]. Although the tumor in this case had G3 NEC features, neither small or large cell histology was identified. This is an example of how the current classification does not encompass all tumor types, making final determination and treatment direction ambiguous when these rare instances are encountered.

Tumor heterogeneity is an obstacle for proper tumor classification in a particular NENs subgroup; however, this is not a rare phenomenon in well-differentiated NETs [25]. Several previous reports showed that mitotic rate and ki-67 index can vary within one specimen and between the primary and metastases in GEP NENs [14,26]. Tang, et al. reported in their retrospective review of 31 GEP G1 NET cases, that the G3 component occurred in 48% of the primary tumors and in 52% of metastatic sites [13]. In contrast, tumor heterogeneity is quite uncommon in poorly differentiated NECs which typically present with consistent ki-67 > 20% [27]. In the presented case, postoperative assessment of the primary tumor revealed a G3 NEC with ki-67 up to 25% (Figure 5a and Figure 5b). However, a preoperative biopsy from the metastatic lesion showed a well-differentiated G1 NET with ki-67 < 3% and mitotic rate of < 1 per 10 HPF. Therefore, it might be reasonable to consider a biopsy of different metastatic sites, but this is not always feasible [13,25]. Without surgical exploration, it can be difficult to identify the primary tumor, therefore serial imaging can help determine if the tumor biology is concordant with the pathology results.

The clinical decisions in heterogeneous tumors are difficult as they cannot be based only on tumor grade. Expression of somatostatin receptors (SRs) status, which defines the efficacy of treatment with somatostatin analogs and peptide receptor radionuclide therapy, might be helpful in the treatment of this group of patients. Historically, high expression of SRs is a common diagnostic indicator of well-differentiated G1-G2 NETs, whereas poorly differentiated G3 NECs express few, if any, SRs [28,29]. Therefore, somatostatin analogs are usually preferred for G1-G2 NETs and uncommonly administered in patients with G3 NEC [12]. However, several studies reported that up to 40-50% G3 NECs demonstrate active tracer uptake at somatostatin receptor-based imaging (particularly Ga-68 DOTATATE PET) [20,30,31]. Potentially, functional imaging can be used for prediction of response to somatostatin analog therapy based on the activity of tracer uptake [27]. In Koch, et al.’s study, the administration of octreotide demonstrated longer PFS in NET patients who had higher tracer uptake (standardized uptake value [SUV] > 20.3) on Ga-68 DOTATATE PET compared to patients with low SUV (69 and 26 weeks, respectively) [32]. In the presented case, Ga-68 DOTATATE PET-MRI also visualized several lesions with SRs (Figure 2a, Figure 2b, Figure 2c and Figure 2d) with maximal SUV of 28. This allowed us to consider long-acting somatostatin analogs for treatment, despite G3 NEC pathology.

In contrast, chemotherapy has shown effectiveness in the treatment of poorly differentiated G3 NECs and no benefit in patients with G1-G2 NETs, making treatment decisions of heterogeneous tumors challenging [11,12]. In addition, several studies indicate that the efficacy of chemotherapy varies within G3 tumors. Velayoudom-Cephise, et al. showed no treatment response to cisplatin-based chemotherapy in patients with well-differentiated G3 NETs in comparison with a 31% rate of response in patients with G3 NECs [20]. Another study showed worse response to chemotherapy in 15% of patients with ki-67 < 55%, while treatment
response with ki-67 > 55% was seen in 42% [33]. This data demonstrates that the G3 group might be heterogeneous in clinical behavior and clinical management of these tumors should not be based solely on tumor grade. In the presented case, final pathology showed a poorly differentiated tumor with maximal ki-67 of 25% and multiple foci of ki-67 < 20%. The current clinical guidelines have not provided treatment algorithms for poorly differentiated G3 NECs tumors with a low proliferative rate [11,12]. However, considering existing data, we assumed that the pathology characteristics of this tumor were not favorable for significant treatment response. Additional data is clearly needed to help guide the management of G3 patients with a low proliferative rate.

Molecular testing of GEP NENs can be a promising tool for choosing treatment options. For instance, pancreatic NEC patients with mutated KRAS and loss of Rb showed a much higher response rate for platinum-based chemotherapy than those with wild-type KRAS and retained Rb, 100% vs. 18%, respectively [34]. Despite a lack of data about the correlation between specific mutations and treatment response in small bowel NENs, there are some genetic mutations that can be helpful for clinical management. In a systematic review of 33 retrospective studies and 8 case reports, the molecular features of GEP NECs were assessed and the presence of TP53 mutation was reported in 57-100% and loss of Rb was detected in 44-56% of cases [35]. Although there were no molecular alterations in the presented case, we believe molecular testing might be useful for neuroendocrine tumors to determine additional treatment options.

Current WHO classification is designed to guide treatment and prognosis for all NENs. Unfortunately, because of heterogeneity of these neoplasms, physicians are challenged to treat patients with tumors that cannot be defined to any of the known NEN subtypes at this current time. Considering all clinical and diagnostic data, we decided that the patient was currently a good candidate for long-acting octreotide for diarrhea symptom management. We hope that it will also help with tumor control, but that will be hard to determine as she has no measurable disease at this time. The patient is being closely monitored further treatment options will be determined based on pattern and timing of recurrence.

Conclusion

This case report demonstrates the diagnostic and treatment challenges of rare heterogeneous small bowel poorly differentiated NEC. We believe that our experience can help to better clarify the challenges of the current WHO classification and clinical trial design for these patients in the future.

Financial Support Disclosure Statements for Each Author

Authors have no financial support to disclose.

Conflict of Interest Statements for Each Author

Andrei Nikiforchin, Ruth Y. Peng, and Michelle Sittig declare that they have no competing interests. Sandy Kotiah reports being a speaker for Novartis and Ipsen.

Contribution

Sandy Kotiah and Andrei Nikiforchin had the idea for the concept of this manuscript. Andrei Nikiforchin designed the paper, made literature search, and wrote the first manuscript draft. Ruth Y. Peng reviewed the pathology specimens and provided the images. Sandy Kotiah and Michelle Sittig reviewed the manuscript, edited it for English, stylistics, and grammar. Sandy Kotiah performed the final manuscript review. All authors contributed to the review and amendments of the manuscript for important intellectual content and approved the final version for submission.

References


